MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sampath, D.
Right arrow Articles by Plunkett, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sampath, D.
Right arrow Articles by Plunkett, W.

Vol. 62, Issue 3, 680-688, September 2002

Inhibition of Cyclin-Dependent Kinase 2 by the Chk1-Cdc25A Pathway during the S-Phase Checkpoint Activated by Fludarabine: Dysregulation by 7-Hydroxystaurosporine

Deepa Sampath, Zheng Shi, and William Plunkett

Department of Experimental Therapeutics, the University of Texas M. D. Anderson Cancer Center, Houston, Texas

Human myeloid leukemia ML-1 cells responded to cytostatic concentrations of fludarabine nucleoside (F-ara-A) by instituting an arrest in S-phase that involved the inhibition of cyclin-dependent kinase 2 (Cdk2). This seemed to be mediated by 1) persistent phosphorylation on the Tyr15 residue of Cdk2 and 2) an increased association of Cdk2 with p21. S-phase arrest was also associated with an increase in Chk1 kinase activity. Concomitantly, the activity of Cdc25A phosphatase was decreased. Immunoprecipitation studies demonstrated complexes of Cdk2, Cdc25A, and Chk1. The addition of the Chk1 kinase inhibitor 7-hydroxystaurosporine (UCN-01) to F-ara-A-arrested S-phase cells resulted in a rapid decrease in the fraction of cells with an S-phase DNA content and a corresponding increase in the fraction of apoptotic cells. Under these conditions, the kinase activity of Chk1 was reduced, Cdc25A phosphatase activity was increased, the level of Tyr15 phosphorylation of Cdk2 was reduced, and the kinase activity associated with immunoprecipitates of Cdk2 and cyclin A was reactivated. UCN-01 also had no effect on the association of p21 with Cdk2. Lastly, cells incubated with UCN-01 before F-ara-A addition did not arrest in S-phase. Thus, the DNA damage induced by F-ara-A initiated a hierarchical regulatory cascade through Chk1 and Cdc25A that resulted in Cdk2 inhibition, affecting an S-phase checkpoint that was dysregulated by UCN-01. These results suggest a mechanism by which UCN-01 enhances the cytotoxicity of agents that cause an S-phase arrest.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Cancer Res.Home page
B. Ewald, D. Sampath, and W. Plunkett
ATM and the Mre11-Rad50-Nbs1 Complex Respond to Nucleoside Analogue-Induced Stalled Replication Forks and Contribute to Drug Resistance
Cancer Res., October 1, 2008; 68(19): 7947 - 7955.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. D. Zabludoff, C. Deng, M. R. Grondine, A. M. Sheehy, S. Ashwell, B. L. Caleb, S. Green, H. R. Haye, C. L. Horn, J. W. Janetka, et al.
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
Mol. Cancer Ther., September 1, 2008; 7(9): 2955 - 2966.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
C. Stolfi, D. Fina, R. Caruso, F. Caprioli, M. C. Fantini, A. Rizzo, M. Sarra, F. Pallone, and G. Monteleone
Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase
Carcinogenesis, June 1, 2008; 29(6): 1258 - 1266.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
B. Ewald, D. Sampath, and W. Plunkett
H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation
Mol. Cancer Ther., April 1, 2007; 6(4): 1239 - 1248.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Q. Yao, B. Weigel, and J. Kersey
Synergism between Etoposide and 17-AAG in Leukemia Cells: Critical Roles for Hsp90, FLT3, Topoisomerase II, Chk1, and Rad51
Clin. Cancer Res., March 1, 2007; 13(5): 1591 - 1600.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. McGahren-Murray, N. H.A. Terry, and K. Keyomarsi
The Differential Staurosporine-Mediated G1 Arrest in Normal versus Tumor Cells Is Dependent on the Retinoblastoma Protein
Cancer Res., October 1, 2006; 66(19): 9744 - 9753.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Sampath, J. Cortes, Z. Estrov, M. Du, Z. Shi, M. Andreeff, V. Gandhi, and W. Plunkett
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial
Blood, March 15, 2006; 107(6): 2517 - 2524.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis
Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway
Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. A. Mesa, D. Loegering, H. L. Powell, K. Flatten, S. J. H. Arlander, N. T. Dai, M. P. Heldebrant, B. T. Vroman, B. D. Smith, J. E. Karp, et al.
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine
Blood, July 1, 2005; 106(1): 318 - 327.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
L. M. Karnitz and S. J. H. Arlander
Chk1, a Novel Target to Sensitize Tumor Cells to Replication Inhibitors
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 254 - 257.
[Full Text] [PDF]


Home page
Cancer Res.Home page
L. A. Parsels, J. D. Parsels, D. C.-H. Tai, D. J. Coughlin, and J. Maybaum
5-Fluoro-2'-Deoxyuridine-Induced cdc25A Accumulation Correlates with Premature Mitotic Entry and Clonogenic Death in Human Colon Cancer Cells
Cancer Res., September 15, 2004; 64(18): 6588 - 6594.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Loegering, S. J. H. Arlander, J. Hackbarth, B. T. Vroman, P. Roos-Mattjus, K. M. Hopkins, H. B. Lieberman, L. M. Karnitz, and S. H. Kaufmann
Rad9 Protects Cells from Topoisomerase Poison-induced Cell Death
J. Biol. Chem., April 30, 2004; 279(18): 18641 - 18647.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. C. Maggio, R. R. Rosato, L. B. Kramer, Y. Dai, M. Rahmani, D. S. Paik, A. C. Czarnik, S. G. Payne, S. Spiegel, and S. Grant
The Histone Deacetylase Inhibitor MS-275 Interacts Synergistically with Fludarabine to Induce Apoptosis in Human Leukemia Cells
Cancer Res., April 1, 2004; 64(7): 2590 - 2600.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. J. H. Arlander, A. K. Eapen, B. T. Vroman, R. J. McDonald, D. O. Toft, and L. M. Karnitz
Hsp90 Inhibition Depletes Chk1 and Sensitizes Tumor Cells to Replication Stress
J. Biol. Chem., December 26, 2003; 278(52): 52572 - 52577.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics